In patients undergoing percutaneous coronary intervention (PCI), intensifying antiplatelet therapy based on platelet reactivity testing reduces cardiovascular mortality and stent thrombosis, according ...

Researchers have identified serine threonine kinase 10 as a key regulator of platelet function, haemostasis and ...

Ado-trastuzumab emtansine (T-DM1) treatment results in grade 3-4 thrombocytopenia in 8%-13% of patients. Prior in vitro studies reported T-DM1 inhibition of megakaryocyte maturation as the cause of ...

Haemonetics Corporation HAE recently initiated commercial roll out of its four-channel TEG 6s PlateletMapping ADP & AA assay cartridge globally. Designed to be used with the TEG 6s Hemostasis Analyzer ...

Patients on prasugrel therapy have greater platelet inhibition than those taking maintenance doses of clopidogrel and thus require a longer time to return to baseline reactivity after stopping the ...

Barcelona, Spain, 31 August: Studies from a growing body of convincing data show that responsiveness to antiplatelet therapy is real. This is a clinically important issue and there is a need to ...

Megakaryocytes, which are derived from hematopoietic stem cell precursors in bone marrow, form and release platelets; these circulate in the blood for 8 to 10 days before they are removed by hepatic ...

February 2, 2007 (Jacksonville, FL) - A 150-mg maintenance dose of clopidogrel may be more appropriate than the standard 75-mg dose for patients with type 2 diabetes who are at higher risk of ...